You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

42 Results
Drug
Other Name(s): Vidaza®
Sep 2025
Drug
Other Name(s): Arimidex®
Jun 2025
Drug
Other Name(s): Alecensaro®
Sep 2025
Drug
Other Name(s): Tecentriq™
Jul 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML), 
Myelodysplastic Syndrome (MDS), 
Myeloproliferative Neoplasms (MPNs)
Intent: Palliative
Funding:
New Drug Funding Program
    Azacitidine - Intermediate-2 and high-risk myelodysplastic syndrome (MDS)
New Drug Funding Program
    Azacitidine - Acute Myeloid Leukemia (AML)
New Drug Funding Program
    Azacitidine - Acute Myeloid Leukemia (AML) Greater Than 30% Blasts
Jul 2023
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Drugs Used:
alemtuzumab (Compassionate),
riTUXimab (Unfunded)
Nov 2023
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
Exceptional Access Program
    alectinib - Treatment of ALK-positive locally advanced or metastatic non-small cell lung cancer, according to criteria
Sep 2025
Regimen
Cancer Type:
Skin, 
Merkel Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Avelumab - Metastatic Merkel Cell Carcinoma
Jan 2025
Drug
Other Name(s): Bavencio™
Jan 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Atezolizumab - Advanced or Metastatic Non-Small Cell Lung Cancer
New Drug Funding Program
    Atezolizumab - Advanced or Metastatic Non-Small Cell Lung Cancer
Jun 2025
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    anastrozole
Exceptional Access Program
    ribociclib - For the treatment of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER 2)-negative, unresectable locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant according to clinical criteria
Sep 2025
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    anastrozole
Exceptional Access Program
    palbociclib - For the treatment of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER 2)-negative, unresectable locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant, according to clinical criteria
Sep 2025

Pages